SAM
CGEM icon

Smartleaf Asset Management’s Cullinan Oncology CGEM Stock Holding History

Smartleaf Asset Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$349 Hold
26
– – ﹤0.01% 3273
2025
Q4 		$258 Buy
+26
New +$235 ﹤0.01% 3339

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Smartleaf Asset Management's CGEM Position: Q1 2026 in Review

Smartleaf Asset Management held its Cullinan Oncology (CGEM) position steady in Q1 2026 at 26 shares worth $349. The position accounts for ﹤0.01% of the portfolio, ranked #3273.

Smartleaf Asset Management first reported a position in CGEM in Q4 2025 and has held it in 2 quarters since. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

  • Smartleaf Asset Management held 26 shares of Cullinan Oncology worth $349 as of Q1 2026.
  • Smartleaf Asset Management left its Cullinan Oncology share count unchanged in Q1 2026.
  • Cullinan Oncology made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #3273 holding.
  • Smartleaf Asset Management first reported a position in Cullinan Oncology in Q4 2025 and has held it in 2 quarters since.
  • 174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.